Ticker
SCLP
Analysis
Scancell Holdings Plc investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to SCLP.
Scancell Holdings Plc investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to SCLP.
SCLP
Stock
$284.4M
Health Technology
Biotechnology
GBX
Scancell Holdings Plc may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.
Potent and durable efficacy with iSCIB1+ of 77% progression free survival (PFS) at 20 months, in combination with ipilimumab and nivolumab, demonstrated in the Phase 2 SCOPE tri...
Scancell Holdings plc announced a CFO transition with David Schilansky appointed as financial advisor and interim CFO, effective immediately, to ensure continuity as the company...
OXFORD, United Kingdom, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies to treat cancer, t...
Scancell Holdings plc reported interim results for the six months ended 31 October 2025, with an operating loss of £8.9 million, an improvement from £10.5 million in the prior y...
Scancell Holdings plc announced that the FDA has cleared its Investigational New Drug application for a Phase 3 trial of iSCIB1+ in advanced melanoma, with progression-free surv...
Review valuation context for Scancell Holdings Plc.
Review future growth context for Scancell Holdings Plc.
Review past performance context for Scancell Holdings Plc.
Review financial health context for Scancell Holdings Plc.
Review dividend context for Scancell Holdings Plc.
Review management context for Scancell Holdings Plc.
Review ownership context for Scancell Holdings Plc.
Review other information context for Scancell Holdings Plc.
Review community context for Scancell Holdings Plc.